Communiquer plus efficacement en prévention. Modèle intégratif et recommandations à l’usage des professionnels de la santé publique

Broc, Guillaume; Edjolo, Arlette

doi:10.1016/j.respe.2016.08.005

Cited by 1 publication

(1 citation statement)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data used come from the SNDS, which contains comprehensive healthcare reimbursement data for all individuals covered by the SHI. This database has been described by Tuppin et al [19] and contains in particular: demographic characteristics concerning beneficiaries; diagnoses information for beneficiaries under the for “ALD” status which waives co-payments related to some specific long-term diseases, but also for hospitalisation stays, sick leaves (lasting 6 months and longer), and disability pensions; the dates of death of beneficiaries, when applicable; reimbursement data: primary care (types and dates of procedures performed by private physicians, dentists, etc. ; medical devices and associated services, reimbursed drugs, etc.…”

Section: Methodsmentioning

confidence: 99%

Impact of type 2 diabetes on health expenditure: estimation based on individual administrative data

et al. 2019

View full text Add to dashboard Cite

Only limited data are available in France on the incidence and health expenditure of type 2 diabetes. The objective of this study, based on national health insurance administrative database, is to describe the expenditure reimbursed to patients newly treated for type 2 diabetes and the proportion of expenditure attributable to diabetes. The study is conducted over a 6-year period from 2008, the year of incidence of treated diabetes, to 2014. Type 2 diabetic patients aged 45 years and older are identified on the basis of their drug consumption. To estimate expenditure attributable to diabetes, a matched control group is selected among more than 13 million beneficiaries over 44 years old not taking antidiabetic treatment. The expenditure attributable to diabetes is estimated by two methods: simple comparison of reimbursed health expenditure between both groups, and a difference-in-differences method including control variables. The cohort of incident type 2 diabetic patients comprises 170,013 patients in 2008. Mean global reimbursed expenditure is €4700 per patient in 2008 and €5500 in 2015. Expenditure attributable to diabetes, estimated by direct comparison with controls, is €1500 in the first year. We, thus, observe a decrease in the following year due to decreased hospitalisations, and then expenditure increase by an average of 7% per year to reach €1900 in the eighth year after the initiation of treatment.

show abstract

Section: Methodsmentioning

confidence: 99%